Petosemtamab, CAS 2213450-26-9

Product Description: Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC)[1][2].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Antoine Hollebecque, et al. Abstract P185: Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma. Mol Cancer Ther (2021) 20 (12_Supplement): P185./[2]Guillem Argiles, et al. Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC). Journal of Clinical Oncology 39, no. 3_suppl

CAS Number: 2213450-26-9

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: EGFR

• Artikelnummer: MEXHY-P99406-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99406-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK